NASDAQ · BBOT
Healthcare · Biotechnology
$3.50
Down-$0.10 (-2.78%)
Updated Oct 7, 2026, 2:50 AM
SID Score
3.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · BBOT
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 6, 2026
BBOT closed at $3.50 after 21 trading sessions, down 60.50% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 6, 2026 | $3.60 | $3.72 | $3.48 | $3.50 | 660.11K |
| Oct 5, 2026 | $3.88 | $3.88 | $3.575 | $3.60 | 481.65K |
| Oct 2, 2026 | $3.97 | $4.045 | $3.88 | $3.89 | 486K |
| Oct 1, 2026 | $4.05 | $4.10 | $3.82 | $3.94 | 1.36M |
| Sep 30, 2026 | $3.94 | $4.15 | $3.875 | $4.10 | 736.32K |
| Sep 29, 2026 | $3.83 | $4.02 | $3.80 | $3.92 | 537.35K |
| Sep 28, 2026 | $3.91 | $3.925 | $3.79 | $3.81 | 476.63K |
| Sep 25, 2026 | $4.00 | $4.00 | $3.89 | $3.95 | 523.56K |
| Sep 24, 2026 | $4.15 | $4.17 | $3.90 | $3.99 | 656.66K |
| Sep 23, 2026 | $4.61 | $4.70 | $4.05 | $4.16 | 540.25K |
| Sep 22, 2026 | $4.63 | $4.81 | $4.60 | $4.66 | 509.12K |
| Sep 21, 2026 | $4.84 | $4.84 | $4.594 | $4.66 | 468.73K |
| Sep 18, 2026 | $4.86 | $4.86 | $4.69 | $4.77 | 1.23M |
| Sep 17, 2026 | $4.84 | $5.10 | $4.84 | $4.89 | 417.38K |
| Sep 16, 2026 | $4.93 | $4.99 | $4.71 | $4.76 | 855.55K |
| Sep 15, 2026 | $5.01 | $5.015 | $4.72 | $4.88 | 629.2K |
| Sep 14, 2026 | $4.91 | $5.18 | $4.85 | $5.05 | 956.1K |
| Sep 11, 2026 | $5.53 | $5.616 | $4.90 | $4.95 | 1.63M |
| Sep 10, 2026 | $6.785 | $6.785 | $5.48 | $5.52 | 2.79M |
| Sep 9, 2026 | $8.86 | $8.86 | $6.295 | $6.755 | 1.5M |
| Sep 8, 2026 | $8.88 | $9.05 | $8.775 | $8.86 | 154.11K |
The latest Smart Investors Daily articles mentioning BBOT.
Company
Market Activity
Research & News
BBOT research
Company profile and research snapshot.
BridgeBio Oncology Therapeutics Inc, formerly BridgeBio Oncology Therapeutics is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 11, 2026 | JP Morgan | Overweight | — |
| Sep 10, 2026 | Leerink Partners | Outperform | — |
| Sep 9, 2026 | Wedbush | Outperform | — |
| Sep 9, 2026 | Stifel | Buy | — |
| Sep 9, 2026 | Raymond James | Outperform | — |
No generated briefing is available yet.
Yahoo · Sep 12, 2026
On September 8, BridgeBio Oncology Therapeutics (NASDAQ:BBOT) released new clinical data for its lead KRASG12C inhibitor, BBO-8520, and used the moment to narrow its focus: the company is now prioritizing BBO-8520 paired with a checkpoint inhibitor in previously treated lung cancer patients, alongside combination work for its two earlier-stage assets, BBO-11818 and BBO-10203, in other […]
Benzinga · Sep 10, 2026
Leerink Partners analyst Andrew Berens maintains BridgeBio Oncology (NASDAQ:BBOT) with a Outperform and lowers the price target from $39 to $27.
Benzinga · Sep 9, 2026
Canaccord Genuity analyst John Newman maintains BridgeBio Oncology (NASDAQ:BBOT) with a Buy and lowers the price target from $23 to $20.
Benzinga · Sep 9, 2026
Raymond James analyst Sean McCutcheon maintains BridgeBio Oncology (NASDAQ:BBOT) with a Outperform and lowers the price target from $24 to $22.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning BBOT.
